US Penicillin G Sodium prices eased through February as comfortable import availability and orderly Gulf logistics reduced upward spot pressure. Early February, offers slipped as steady exports from Chinese and Indian manufacturers increased cargo, while mid-month arrivals into Houston moved without abnormal dwell times. Late-month reports showed importers carrying adequate pipeline stocks and refraining from chasing spot tonnage, reinforcing downward momentum. Demand patterns were mixed: stronger requirements from neurological drug makers contrasted with muted buying from hospitals and livestock users, leaving the market leaning toward softer pricing by month end. Hospitals softened purchase cadence, with formulary utilisation growth constrained by antimicrobial stewardship programmes, while livestock buyers substituted toward non-medicated premixes and restrained incremental buying. Neurological drug manufacturers remained a core source of demand. Asian manufacturing hubs account for the bulk of US imports, heightening sensitivity to exporter allocation and shipping conditions. Looking ahead, the market faces upward pressure in spring but could moderate through summer, contingent on freight dynamics.
